ConjuChem Biotechnologies Reports PC-DAC(TM):Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting



    MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today
announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin
Conjugate for the treatment of Type 2 diabetes will be presented at the 67th
Scientific Sessions of the American Diabetes Association (ADA) to be held
June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting
is one of the largest gatherings of health care professionals involved in
diabetes research and the delivery of diabetes care.
    "These encouraging results from our Phase I/II multiple-dose clinical
studies demonstrate that our PC-DAC(TM):Exendin-4 Albumin Conjugate is a
well-tolerated and effective therapy," said Mark D. Perrin, President and CEO.
"The data was further evidence of our compound's potential to become a
once-weekly treatment for Type 2 diabetes."
    The study titled "PC-DAC(TM):Exendin-4 (CJC-1134-PC) Demonstrates Safety
and Efficacy as an Adjunct Therapy to Metformin: A Randomized, Double-Blind,
Placebo-Controlled, One Month Phase I/II Study in 70 Patients with Type 2
Diabetes Mellitus", authored by Maggie Wang et al., was featured as a late
breaking abstract. Seventy patients were enrolled in US and Canada and
randomized to 1 mg, 2mg, 3mg of PC-DAC(TM):Exendin-4 or placebo treatment
groups.  All three treatment groups experienced reductions in fasting plasma
glucose that were statistically significant versus baseline (p less than
0.005) and versus placebo (p less than 0.03) over the 5-week treatment period.
Median HbA1c values decreased from baseline by 0.7%, 0.8% and 0.9% in the 1mg,
2mg, and 3mg groups, respectively, at the end of the study (Day 63) and were
statistically significant (p less than 0.03 by ANCOVA) between pooled active
patients (n=52) and placebo (n=18). There was no significant change in weight
in the treatment cohorts (baseline 81-85kg) at the end of the treatment
period. Generally low-titer antibodies were detected in 11/52 treated
patients. The drug was well-tolerated with no drug-related serious adverse
events during the study.
    In addition, the study titled "Safety and Pharmacodynamics of
CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes
Mellitus: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation
Study", authored by Maggie Wang et al., was also featured as a poster session.
This study evaluated the safety and efficacy of escalating single doses of
CJC-1134-PC in 58 patients who had discontinued their oral antidiabetic agents
for greater than or equal to 1 week and were randomized to either active drug
or placebo in 6 escalating cohorts (PC-DAC(TM):Exendin-4 from 0.31mg to
5.0mg). Doses of greater than or equal to 1.25mg produced rapid and
long-lasting reductions in mean daily glucose and fasting plasma glucose
levels, persisting for at least 7 days after the single injection. In a
separate cohort of 16 patients (12 active and 4 placebo) treated with either a
single dose of 3mg PC-DAC(TM):Exendin-4 or placebo, a mean reduction in body
weight of 2.5 kg (vs. 1.2 kg for placebo) was observed at the end of the
3-week in-clinic stay on a controlled diet. No significant safety or
tolerability issues were reported at dose levels up to 3 mg.
    Abstracts for the event can be found on the ADA's website at
http://scientificsessions.diabetes.org.

    About PC-DAC(TM):Exendin-4

    Exendin-4, like Glucagon-like peptide-1 (GLP-1) is an insulinotropic
peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon
and increases insulin secretion in a glucose-dependent manner. Exendin-4 may
stimulate beta-cell proliferation, restore beta-cell sensitivity to glucose,
delay gastric emptying, and increase peripheral sensitivity to glucose. The
clinical utility of Exendin-4 is somewhat limited by its relatively short
half-life in plasma. Developed with ConjuChem's proprietary PC-DAC(TM)
technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analogue that is
covalently bound to recombinant human albumin (Recombumin(R), provided by
Novozymes Delta Limited). Data from Phase I/II clinical studies have
demonstrated that the preformed albumin-peptide conjugate has a much longer
half-life than the peptide alone. The product is a highly soluble liquid
formulation that is injectable in a small volume with a small gauge needle.

    About ConjuChem

    ConjuChem, developer of next generation medicines from therapeutic
peptides, is creating long-acting compounds based on bioconjugation platform
technologies. When applied to peptides, the Company's systemic DAC(TM) and
PC-DAC(TM) Technologies enable the creation of new drugs with significantly
enhanced therapeutic properties as compared to the original peptide. Detailed
descriptions of the Company can be viewed on the Company's website
www.conjuchem.com.





For further information:

For further information: Lennie Ryer, CA, Vice President Finance, CFO,
ConjuChem Biotechnologies Inc., (514) 844-5558 ext 224, ryer@conjuchem.com;
Michael Polonsky, Investor Relations, (416) 815-0700 ext. 231, (416) 815-0080,
mpolonsky@equicomgroup.com

Organization Profile

CONJUCHEM BIOTECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890